IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 301-325 out of 1339.

<< < 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 > >>

Public Release: 20-Apr-2016
Nature Communications
Brain stem cell quiescence needs to be actively maintained in Drosophila
Biologists at Johannes Gutenberg University Mainz in Germany have discovered that the phases of quiescence in the Drosophila fruit fly central nervous system are controlled by the Hippo signaling pathway.

Contact: Dr. Christian Berger
Johannes Gutenberg Universitaet Mainz

Public Release: 20-Apr-2016
Taking aspirin could increase cancer survival by 20 percent
Patients receiving cancer treatment could increase their chance of survival by up to 20 percent and help stop their cancer from spreading by taking a low dose of aspirin, new research suggests.

Contact: Peter Elwood
Cardiff University

Public Release: 20-Apr-2016
Science Translational Medicine
Study finds explanation for some treatment-resistant breast cancers
The new study led by Vanderbilt-Ingram Cancer Center investigators has identified gene alterations that may explain why triple-negative breast cancer is resistant to most existing treatments, and suggests that a targeted therapy currently in clinical development may prove beneficial.
IBC Network Foundation, US Department of Defense, and NIH/National Cancer Institute

Contact: Craig Boerner
Vanderbilt University Medical Center

Public Release: 20-Apr-2016
Nature Communications
Targeted missiles against aggressive cancer cells
Targeted missiles that can enter cancer cells and deliver lethal cell toxins without harming surrounding healthy tissue. This has been a long-standing vision in cancer research, but it has proved difficult to accomplish. A research group at Lund University in Sweden has now taken some crucial steps in this direction.

Contact: Cecilia Schubert
Lund University

Public Release: 20-Apr-2016
American Association for Cancer Research 2016 Annual Meeting
AACR: Targeting cancer with engineered T cells
Dr. Philip Greenberg, head of immunology and a member of the Clinical Research Division at Seattle's Fred Hutchinson Cancer Research Center and a leader in cancer immunology, will describe at AACR 2016 how he and colleagues are genetically engineering T cells to seek out cancer cells, penetrate their defenses and kill them.

Contact: Rhonda Curry
Fred Hutchinson Cancer Research Center

Public Release: 20-Apr-2016
Cancer Microenvironment
Stomach cancer diagnostics: New insights on stage of tumor growth
Researchers of Kazan Federal University and the National Academy of Sciences of Ukraine found correlations between the superoxide and nitric oxide generation rates, levels of active forms of MMP-2 and MMP-9 in tumor and adjoining tissues between each other and with the disease stages for gastric cancer patients.

Contact: Yevgeniya Litvinova
Kazan Federal University

Public Release: 20-Apr-2016
JAMA Oncology
Detecting when the most common skin cancer turns dangerous
A team of researchers who specialize in treating cancers of the eye wanted to identified EZH2 as a marker for aggressive basal cell skin cancer. It may also provide a potential target for treatment.
National Institutes of Health, Genentech, Research to Prevent Blindness, NIH/National Eye Institute

Contact: Nicole Fawcett
University of Michigan Health System

Public Release: 20-Apr-2016
UMN researchers show 'dirty mice' could clean up immune system research
Scientists at the University of Minnesota have developed a new way to study mice that better mimics the immune system of adult humans and which could significantly improve ways to test potential therapeutics. Published online today in the journal Nature, the researchers describe the limitations of laboratory mice for immunology research and reveal the benefits of what they are calling 'dirty mice.'
National Institutes of Health

Contact: Caroline Marin
University of Minnesota Academic Health Center

Public Release: 19-Apr-2016
American Association for Cancer Research 2016 Annual Meeting
New England Journal of Medicine
Immunotherapy drug shrinks tumors in half of patients with rare, virus-linked skin cancer
In a clinical trial of the immunotherapy drug pembrolizumab, half of 25 patients with a rare type of virus-linked skin cancer called Merkel cell carcinoma experienced substantial tumor shrinkage lasting nearly three times as long, on average, than with conventional chemotherapy. Several patients had no remaining evidence of disease.
NIH/National Cancer Institute, Merck

Contact: Vanessa Wasta
Johns Hopkins Medicine

Public Release: 19-Apr-2016
Human Reproduction
BRCA1 gene mutation is linked to women having fewer eggs in their ovaries
Researchers have discovered a link between the BRCA1 gene mutation and lower levels of a hormone that is an indicator of the number of eggs left in a woman's ovaries, according to research published in Human Reproduction, one of the world's leading reproductive medicine journals.
Australian National Breast Cancer Foundation

Contact: Emma Mason
European Society of Human Reproduction and Embryology

Public Release: 19-Apr-2016
American Association for Cancer Research 2016 Annual Meeting
Merkel cell carcinoma patients who received pembrolizumab often had durable responses
In a phase 2 clinical trial of the immunotherapy drug pembrolizumab as a first-line systemic therapy for advanced Merkel cell carcinoma, or MCC -- a rare, aggressive type of skin cancer -- the clinical response rate was similar to that typically seen with standard chemotherapy, but the duration of the response appeared to be markedly longer. There are currently no therapies that have been approved by the US Food and Drug Administration for this cancer.
NIH/National Cancer Institute

Contact: Rhonda Curry
Fred Hutchinson Cancer Research Center

Public Release: 19-Apr-2016
Science Signaling
Scientists propose treatment for severe lung diseases
Researchers are developing a new drug to treat life-threatening lung damage and breathing problems in people with severe infections like pneumonia, those undergoing certain cancer treatments and premature infants with underdeveloped, injury prone lungs. Scientists at Cincinnati Children's Hospital Medical Center report April 19, 2016 in Science Signaling that a transcription factor called FOXF1 activates several biological processes that promote recovery from acute lung injury.

Contact: Nick Miller
Cincinnati Children's Hospital Medical Center

Public Release: 19-Apr-2016
Pediatric Blood and Cancer
Rare pediatric cancer successfully treated with new targeted therapy
When a baby's life was threatened by a rare pediatric cancer that would not respond to surgery or chemotherapy, doctors at Nemours Children's Hospital rapidly, successfully shrank the tumor by 90 percent using an experimental treatment, according to a new study published online in Pediatric Blood and Cancer. The now-20-month-old girl achieved the remarkable improvement by receiving a drug called LOXO-101 that was being tested on adults, researchers reported.
Loxo Oncology, Inc., Stamford, CT

Contact: Tamara Moore

Public Release: 19-Apr-2016
Trends in Cancer
Are lab mice too cold? Why it matters for science
A typical mouse laboratory is kept between 20 and 26 degrees C, but if the mice had it their way, it would be a warm 30 degrees C. While the mice are still considered healthy at cooler temperatures, they expend more energy to maintain their core temperature, and evidence is mounting that even mild chronic cold stress is skewing results in studies of cancer, inflammation, and more. Researchers review the evidence April 19 in Trends in Cancer.

Contact: Karen Zusi
Cell Press

Public Release: 19-Apr-2016
American Association for Cancer Research Annual Meeting 2016
Pancreatic cancer risk tied to specific mouth bacteria
The presence of certain bacteria in the mouth may reveal increased risk for pancreatic cancer and enable earlier, more precise treatment.

Contact: David March
NYU Langone Medical Center / New York University School of Medicine

Public Release: 19-Apr-2016
New treatment for advanced melanoma shows promise
In a study appearing in the April 19, 2016 issue of JAMA, Antoni Ribas, M.D., Ph.D., of the University of California-Los Angeles, and colleagues examined tumor response and overall survival following administration of the antibody pembrolizumab among patients with advanced melanoma.

Contact: Reggie Kumar
The JAMA Network Journals

Public Release: 19-Apr-2016
Annals of Surgical Oncology
Media coverage of celebrities with breast cancer influencing rise in double mastectomy
An increase in women with breast cancer choosing double mastectomy may be influenced by media coverage of celebrities, a new study finds.

Contact: Nicole Fawcett
University of Michigan Health System

Public Release: 19-Apr-2016
Journal of Clinical Oncology
Breast cancer patients receiving Herceptin treatment should be monitored for heart damage at any age
Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age. This is among the findings of a new study from the Peter Munk Cardiac Centre, the Institute for Clinical Evaluative Sciences and the Ted Rogers Centre for Heart Research, University Health Network.

Contact: Lianne Castelino
University Health Network

Public Release: 19-Apr-2016
Proceedings of the National Academy of Sciences
New class of small molecule drug, SI-2, has potential for improving cancer treatment
Cancer cells communicate with their environment through cell molecules that pass on signals to the inside of the cell. SI-2 is a potent small-molecule inhibitor to drug the undruggable steroid receptor coactivator-3.

Contact: Maribel Mendoza
Baylor College of Medicine

Public Release: 19-Apr-2016
UTSW surgeons develop innovative technique for reconstructing breast after mastectomy
UT Southwestern Medical Center plastic surgeons have developed a new breast reconstruction technique that combines advantages of two different types of microsurgical procedures using abdominal and other tissue to reconstruct the breast after a mastectomy.

Contact: Gregg Shields
UT Southwestern Medical Center

Public Release: 19-Apr-2016
Aspirin use may help prevent bile duct cancer, Mayo-led study finds
A team of current and former Mayo Clinic researchers has discovered that aspirin use is associated with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma. The results are published in Hepatology.

Contact: Joe Dangor
Mayo Clinic

Public Release: 19-Apr-2016
American Association for Cancer Research 2016 Annual Meeting
Immunotherapy is first to show survival benefit in head and neck cancer
The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy.
Bristol Myers Squibb

Contact: Henry French
Institute of Cancer Research

Public Release: 19-Apr-2016
New technology quantifies effects of prostate tumor laser ablation
Researchers at Case Western Reserve University have developed computational tools to use magnetic resonance images to quantitatively evaluate the effects on the form and structure of the prostate following treatment. The image analysis may uncover risks of ablation and whether shape changes are associated with recurrence.
NIH/National Cancer Institute

Contact: Kevin Mayhood
Case Western Reserve University

Public Release: 19-Apr-2016
American Association for Cancer Research
Watercress extract detoxifies carcinogens in smokers, clinical trial demonstrates
Watercress extract taken multiple times a day significantly inhibits the activation of a tobacco-derived carcinogen in cigarette smokers, researchers at the University of Pittsburgh Cancer Institute, partner with UPMC CancerCenter, demonstrated in a phase II clinical trial presented today at the American Association for Cancer Research Annual Meeting in New Orleans.
NIH/National Cancer Institute

Contact: Amy Charley
University of Pittsburgh Schools of the Health Sciences

Public Release: 18-Apr-2016
American Association for Cancer Research 2016 Annual Meeting
Delaying radiation therapy for women with very early breast cancer ups recurrence
Delaying radiation therapy too long after surgery significantly increases the risk of recurrent tumors in women treated for very early, or what is referred to as 'stage 0,' breast cancer, according to new research at Washington University School of Medicine in St. Louis.
The Foundation for Barnes-Jewish Hospital, Breast Cancer Research Foundation

Contact: Jim Goodwin
Washington University School of Medicine

Showing releases 301-325 out of 1339.

<< < 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 > >>

  Search News Releases